 |
NeoSkin/NeoEye
PNPURE™
PNPURE™ stands out in the category of polynucleotide treatment brands as a scientifically engineered, high-purity injectable skin booster designed to restore dermal structure, hydration and resilience from within. Formulated with high-molecular-weight polynucleotides (1260–1570 kDa) derived from sustainably sourced Pacific salmon DNA and refined through the proprietary PUNEXT™ multi-stage purification, PNPURE™ pn injection delivers reliable biocompatibility (raw material DNA similarity to human DNA ~98%) and production purity (>99% PN) that together support robust tissue regeneration while minimising antigenic risk.
Polynucleotides (PN) act as biologically active scaffolds that modulate the dermal microenvironment. PNPURE™ leverages two competitive advantages commonly sought across polynucleotide treatment brands:
· High molecular weight (1260–1570 kDa): larger PN molecules form a more stable three-dimensional matrix inside the dermis, providing prolonged structural support and a persistent stimulus for extracellular matrix (ECM) remodelling.
· Ultra-high purity (PUNEXT™ >99% PN): rigorous removal of protein contaminants reduces inflammatory triggers and improves clinical tolerability—critical for repeat treatment and sensitive areas.
Taken together, these attributes produce measurable clinical benefits: accelerated fibroblast activation, sustained ECM synthesis (collagen I/III, elastin), and durable hydration via indirect restoration of endogenous hyaluronic acid and barrier function.
PNPURE™ is offered as two clinically differentiated preparations to meet distinct treatment needs while remaining under the single PNPURE™ brand promise.
Designed as the flagship product for full-face rejuvenation, PNPURE NeoSkin provides a higher active dose and is optimised to rebuild dermal architecture.
Key formulation highlights
PN concentration: 25 mg/mL (2.5%)
Molecular weight: 1260–1570 kDa
Presentation: 3 mL prefilled syringe; 30G needle
Indication: full-face skin quality improvement, post-procedure support
Clinical rationale and expected effects
· Dermal matrix reconstruction: high PN load supports collagen and elastin neosynthesis, improving firmness and contour.
· Hydration from within: by restoring dermal ECM and promoting HA synthesis, patients report measurable improvements in skin moisture and texture within days.
· Durability: NeoSkin’s formulation is designed to sustain fibroblast activation and ECM upregulation across multiple treatment sessions, offering both immediate and cumulative benefit.
The delicate periocular area requires a gentler, multi-functional approach. PNPURE NeoEye combines PN with supportive actives to hydrate, nourish and protect.
Key formulation highlights
PN concentration: 10 mg/mL
Molecular weight: 1260–1570 kDa
Actives: hyaluronic acid (HA), complex amino acids, carnosine (antioxidant dipeptide)
Presentation: 1 mL prefilled syringe; 30G needle
Indication: tear troughs, periorbital fine lines, and skin laxity around the eyes
Clinical rationale and expected effects
· Gentle yet effective: lower PN concentration and added HA allow targeted hydration with reduced irritation risk.
· Multimodal support: amino acids supply substrates for collagen/elastin production while carnosine provides antioxidant protection against photo-oxidative stress.
· Visible smoothing: patients typically notice decreased crepiness and improved skin clarity in the early post-treatment window, with progressive tightening thereafter.
Mechanistic overview (injection → regeneration)
1. Targeted placement: PNPURE™ is injected into the dermal plane where collagen, elastin and endogenous HA have diminished.
2. Scaffold formation: high-MW PN forms a transient matrix that supports cell migration and mechanical stability.
3. Biological activation: local fibroblasts are stimulated to proliferate and increase ECM synthesis; antioxidant and nutritive co-factors (NeoEye) reduce oxidative damage.
4. Functional improvement: improved dermal density, barrier restoration and hydration lead to smoother, firmer, more luminous skin.
Typical clinical milestones (multi-session protocol)
2–4 days after first session: perceptible smoothing and improved hydration.
2–3 weeks after second session: measurable improvement in tightness, reduced fine lines and clearer skin tone.
3–5 weeks after third session: enhanced lift and fuller appearance as dermal structure strengthens.
After fourth session (and maintenance): long-lasting radiance and resilience, with histological evidence of improved tissue architecture.
Internal preclinical and comparative histology assessments indicate that PNPURE™ produces earlier and more sustained fibroblast activation versus typical non-crosslinked HA. In clinical practice, this translates into durable improvements in skin quality beyond the immediate volumising effect of HA alone. Histological specimens show denser collagen networks and improved dermal thickness following PNPURE™ treatment series—findings that align with the regenerative concept underpinning the product family.
For visual proof of these regenerative results, explore our polynucleotides treatment before and after gallery showcasing authentic patient transformations.
Pricing & procurement: PNPURE™ is positioned to offer premium clinical performance at competitive pricing. Volume discounts and wholesale pricing are available for clinic partners and bulk purchasers.
After-sales: dedicated commercial support for ordering, shipping (regional warehouses available) and clinical training to optimise outcomes.
PNPURE™ products are intended for use by trained medical professionals. The high-purity PUNEXT™ process minimises immunogenic protein contamination and supports a favourable tolerability profile. Standard injection precautions and patient-specific assessment remain essential.
PNPURE™ stands out in the category of polynucleotide treatment brands as a scientifically engineered, high-purity injectable skin booster designed to restore dermal structure, hydration and resilience from within. Formulated with high-molecular-weight polynucleotides (1260–1570 kDa) derived from sustainably sourced Pacific salmon DNA and refined through the proprietary PUNEXT™ multi-stage purification, PNPURE™ pn injection delivers reliable biocompatibility (raw material DNA similarity to human DNA ~98%) and production purity (>99% PN) that together support robust tissue regeneration while minimising antigenic risk.
Polynucleotides (PN) act as biologically active scaffolds that modulate the dermal microenvironment. PNPURE™ leverages two competitive advantages commonly sought across polynucleotide treatment brands:
· High molecular weight (1260–1570 kDa): larger PN molecules form a more stable three-dimensional matrix inside the dermis, providing prolonged structural support and a persistent stimulus for extracellular matrix (ECM) remodelling.
· Ultra-high purity (PUNEXT™ >99% PN): rigorous removal of protein contaminants reduces inflammatory triggers and improves clinical tolerability—critical for repeat treatment and sensitive areas.
Taken together, these attributes produce measurable clinical benefits: accelerated fibroblast activation, sustained ECM synthesis (collagen I/III, elastin), and durable hydration via indirect restoration of endogenous hyaluronic acid and barrier function.
PNPURE™ is offered as two clinically differentiated preparations to meet distinct treatment needs while remaining under the single PNPURE™ brand promise.
Designed as the flagship product for full-face rejuvenation, PNPURE NeoSkin provides a higher active dose and is optimised to rebuild dermal architecture.
Key formulation highlights
PN concentration: 25 mg/mL (2.5%)
Molecular weight: 1260–1570 kDa
Presentation: 3 mL prefilled syringe; 30G needle
Indication: full-face skin quality improvement, post-procedure support
Clinical rationale and expected effects
· Dermal matrix reconstruction: high PN load supports collagen and elastin neosynthesis, improving firmness and contour.
· Hydration from within: by restoring dermal ECM and promoting HA synthesis, patients report measurable improvements in skin moisture and texture within days.
· Durability: NeoSkin’s formulation is designed to sustain fibroblast activation and ECM upregulation across multiple treatment sessions, offering both immediate and cumulative benefit.
The delicate periocular area requires a gentler, multi-functional approach. PNPURE NeoEye combines PN with supportive actives to hydrate, nourish and protect.
Key formulation highlights
PN concentration: 10 mg/mL
Molecular weight: 1260–1570 kDa
Actives: hyaluronic acid (HA), complex amino acids, carnosine (antioxidant dipeptide)
Presentation: 1 mL prefilled syringe; 30G needle
Indication: tear troughs, periorbital fine lines, and skin laxity around the eyes
Clinical rationale and expected effects
· Gentle yet effective: lower PN concentration and added HA allow targeted hydration with reduced irritation risk.
· Multimodal support: amino acids supply substrates for collagen/elastin production while carnosine provides antioxidant protection against photo-oxidative stress.
· Visible smoothing: patients typically notice decreased crepiness and improved skin clarity in the early post-treatment window, with progressive tightening thereafter.
Mechanistic overview (injection → regeneration)
1. Targeted placement: PNPURE™ is injected into the dermal plane where collagen, elastin and endogenous HA have diminished.
2. Scaffold formation: high-MW PN forms a transient matrix that supports cell migration and mechanical stability.
3. Biological activation: local fibroblasts are stimulated to proliferate and increase ECM synthesis; antioxidant and nutritive co-factors (NeoEye) reduce oxidative damage.
4. Functional improvement: improved dermal density, barrier restoration and hydration lead to smoother, firmer, more luminous skin.
Typical clinical milestones (multi-session protocol)
2–4 days after first session: perceptible smoothing and improved hydration.
2–3 weeks after second session: measurable improvement in tightness, reduced fine lines and clearer skin tone.
3–5 weeks after third session: enhanced lift and fuller appearance as dermal structure strengthens.
After fourth session (and maintenance): long-lasting radiance and resilience, with histological evidence of improved tissue architecture.
Internal preclinical and comparative histology assessments indicate that PNPURE™ produces earlier and more sustained fibroblast activation versus typical non-crosslinked HA. In clinical practice, this translates into durable improvements in skin quality beyond the immediate volumising effect of HA alone. Histological specimens show denser collagen networks and improved dermal thickness following PNPURE™ treatment series—findings that align with the regenerative concept underpinning the product family.
For visual proof of these regenerative results, explore our polynucleotides treatment before and after gallery showcasing authentic patient transformations.
Pricing & procurement: PNPURE™ is positioned to offer premium clinical performance at competitive pricing. Volume discounts and wholesale pricing are available for clinic partners and bulk purchasers.
After-sales: dedicated commercial support for ordering, shipping (regional warehouses available) and clinical training to optimise outcomes.
PNPURE™ products are intended for use by trained medical professionals. The high-purity PUNEXT™ process minimises immunogenic protein contamination and supports a favourable tolerability profile. Standard injection precautions and patient-specific assessment remain essential.
